Your browser doesn't support javascript.
loading
UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer.
Goto, Daiki; Komeda, Kazuki; Uwatoko, Natsuki; Nakashima, Moeka; Koike, Mayu; Kawai, Kaho; Kodama, Yuta; Miyazawa, Ayako; Tanaka, Ichidai; Hase, Tetsunari; Morise, Masahiro; Hasegawa, Yoshinori; Kawabe, Tsutomu; Sato, Mitsuo.
Affiliation
  • Goto D; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Komeda K; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Uwatoko N; Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Nakashima M; Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Koike M; Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kawai K; Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kodama Y; Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Miyazawa A; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Tanaka I; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Hase T; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Morise M; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Hasegawa Y; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Kawabe T; National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Sato M; Department of Pathophysiological Laboratory Sciences, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Cancer Invest ; 38(4): 240-249, 2020 Apr.
Article in En | MEDLINE | ID: mdl-32212938
We evaluated the value of UHRF1, a regulator of methylation, as a biomarker for lung cancer. UHRF1 is expressed at higher levels in both lung adenocarcinoma (AD) and squamous cell carcinoma (SQ); however, a meta-analysis showed that UHRF1 expression is correlated with worse survival in patients with AD but not in those with SQ. UHRF1 knockdown suppressed the growth of lung cancer cell lines through G1 cell cycle arrest in some cell lines. These results suggest that UHRF1 may server as a diagnostic marker for AD and SQ and as a prognostic marker for AD in lung cancer.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Biomarkers, Tumor / CCAAT-Enhancer-Binding Proteins / Ubiquitin-Protein Ligases / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Cancer Invest Year: 2020 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Carcinoma, Squamous Cell / Biomarkers, Tumor / CCAAT-Enhancer-Binding Proteins / Ubiquitin-Protein Ligases / Adenocarcinoma of Lung / Lung Neoplasms Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Cancer Invest Year: 2020 Document type: Article